Institutional members access full text with Ovid®

Share this article on:

Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's disease: P-39.

Sands, BE1; Gasink, C2; Gao, L-L2; Blank, MA2; Johanns, J2; Guzzo, C2; Chiou, C-F2; Sandborn, WJ3; Hanauer, SB4; Targan, S5; Rutgeerts, P6; Ghosh, S7; de Villiers, W8; Panaccione, R9; Greenberg, G10; Schreiber, S11; Lichtiger, S1; Feagan, BG12

Inflammatory Bowel Diseases: December 2011 - Volume 17 - Issue - p S24
Clinical Poster Presentations

1Mount Sinai Medical Center, New York, NY, USA,

2Centocor Research & Development, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC., Malvern, PA, USA,

3University of California San Diego, La Jolla, CA, USA,

4University of Chicago, Chicago, IL, USA,

5Cedars-Sinai Medical Center, Los Angeles, CA, USA,

6University Hospital Gasthuisberg, Leuven, Belgium,

7GI Division, University of Calgary, Calgary, AB, Canada,

8University of Kentucky Medical Center, Lexington, Ky, USA,

9IBD Clinic, University of Calgary, Calgary, AB, Canada,

10Mount Sinai Hospital, Toronto, Ontario, Canada,

11Dept of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany,

12Robarts Research Institute, London, Ontario, Canada

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website